| Not Yet Recruiting | NT-3 Levels and Function in Individuals With CMT NCT05011006 | Zarife Sahenk | — |
| Recruiting | A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammator NCT06752356 | Kedrion S.p.A. | Phase 3 |
| Recruiting | Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease NCT07478172 | University of Missouri-Columbia | N/A |
| Not Yet Recruiting | A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases NCT07304154 | Kite, A Gilead Company | Phase 1 |
| Recruiting | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP NCT07091630 | argenx | Phase 3 |
| Enrolling By Invitation | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Followi NCT07072676 | LMU Klinikum | N/A |
| Enrolling By Invitation | An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Poly NCT07188844 | Immunovant Sciences GmbH | Phase 2 |
| Recruiting | Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NCT07154524 | University of Ulm | — |
| Recruiting | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP NCT06920004 | argenx | Phase 3 |
| Not Yet Recruiting | Vitaccess Real CIDP Registry NCT07006597 | Vitaccess Ltd | — |
| Withdrawn | Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy NCT04480450 | University of Kansas Medical Center | Phase 2 |
| Active Not Recruiting | Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP NCT07027111 | Nuvig Therapeutics, Inc. | Phase 2 |
| Recruiting | IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NCT07032662 | Immunovant Sciences GmbH | Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyn NCT06858579 | Dianthus Therapeutics | Phase 3 |
| Completed | A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC NCT06637072 | argenx | Phase 4 |
| Enrolling By Invitation | Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disor NCT06605612 | LMU Klinikum | — |
| Recruiting | A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobul NCT06290141 | Sanofi | Phase 3 |
| Recruiting | Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibili NCT06183645 | Centre Hospitalier Universitaire de Liege | — |
| Unknown | RWE-based Treatment Patterns and Outcomes in CIDP NCT05940922 | RwHealth | — |
| Not Yet Recruiting | Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy NCT05219383 | Assiut University | — |
| Active Not Recruiting | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP NCT05581199 | Immunovant Sciences GmbH | Phase 2 |
| Recruiting | IVIG vs SCIG in CIDP NCT05584631 | Rutgers, The State University of New Jersey | Phase 1 |
| Recruiting | Hizentra® in Inflammatory Neuropathies - pHeNIx Study NCT04672733 | CSL Behring | — |
| Terminated | Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CI NCT03772717 | Emory University | N/A |
| Unknown | A Registered Cohort Study of Immune-Mediated Neuropathies NCT04292834 | First Affiliated Hospital of Fujian Medical University | — |
| Completed | Quantification of Nerve Stiffness in Neuropathies NCT03397303 | Nantes University Hospital | N/A |
| Terminated | Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP NCT03779828 | CSL Behring | — |
| Completed | SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study NCT02967679 | MedDay Pharmaceuticals SA | Phase 2 |
| Withdrawn | Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy NCT02574962 | Mamatha Pasnoor, MD | Phase 2 |
| Completed | IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements NCT02414490 | University of Minnesota | — |
| Unknown | IVIg for Demyelination in Diabetes Mellitus NCT02372149 | University of Toronto | Phase 4 |
| Completed | Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NCT02465359 | University of South Florida | N/A |
| Completed | Effect of Resistance and Aerobic Exercise in CIDP or MMN NCT02121678 | University of Aarhus | N/A |
| Completed | Immunoglobulin Dosage and Administration Form in CIDP and MMN NCT02111590 | Rigshospitalet, Denmark | — |
| Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644 | Sanguine Biosciences | — |
| Completed | Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Poly NCT01824251 | Nihon Pharmaceutical Co., Ltd | Phase 3 |
| Completed | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro NCT01545076 | CSL Behring | Phase 3 |
| Completed | Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy NCT01379833 | State University of New York at Buffalo | — |
| Completed | Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy NCT01184846 | CSL Behring | Phase 3 |
| Completed | Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy NCT00962429 | Oregon Health and Science University | Phase 2 |
| Active Not Recruiting | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases NCT00716066 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy NCT00278629 | Northwestern University | Phase 2 |
| Withdrawn | High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy NCT01236456 | Stony Brook University | Phase 2 |
| No Longer Available | An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NCT04825626 | Hope Biosciences Research Foundation | — |